{"id":15057,"date":"2024-08-07T15:20:00","date_gmt":"2024-08-07T07:20:00","guid":{"rendered":"https:\/\/vaxlab.dukekunshan.edu.cn\/?post_type=evidence-db-expert&p=15057"},"modified":"2025-07-29T15:38:33","modified_gmt":"2025-07-29T07:38:33","slug":"countries-included-pneumococcal-vaccines-in-the-nips","status":"publish","type":"evidence-db-expert","link":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/evidence-db-expert\/pcv-vaccine-evidence-pool\/countries-included-pneumococcal-vaccines-in-the-nips\/","title":{"rendered":"Countries Included Pneumococcal Vaccines in the NIPs"},"content":{"rendered":"\n

The World Health Organization (WHO) recommends the introduction of pneumococcal vaccines into the immunization schedules of all member states. By the end of 2023, 166 countries had done so, with a global coverage rate of approximately 65% for the final PCV dose. Among countries that have introduced PCV, there are 62 high-income countries (31.96%) and 26 low-income countries (13.40%). Of the 28 countries that have not yet introduced PCV into their national immunization programs (NIP), middle-income countries takes the highest proportion, at 67.86% (Table 1).1<\/sup><\/p>\n\n\n\n

Table 1 Number of countries incorporating PCV into national immunization schedules n (%)<\/strong><\/p>\n\n\n\n

Classification of immunization programmes<\/strong><\/td>World Bank Country Income Classification<\/strong><\/td>Number of countries<\/strong><\/td><\/tr>
High-income countries<\/strong><\/td>Middle-income countries<\/strong><\/td>Low-income countries<\/strong><\/td>Other*<\/sup><\/strong><\/td><\/tr>
Included in NIPs<\/td>57 (35.85)<\/td>79 (49.69)<\/td>21 (13.21\uff09<\/td>2\uff081.26)<\/td>159 (81.96)<\/td><\/tr>
For high-risk groups<\/td>2 (28.57)<\/td>5 (71.43)<\/td>0 (0.00\uff09<\/td>0\uff080.00)<\/td>7 (3.61)<\/td><\/tr>
Not included<\/td>3 (10.71)<\/td>19 (67.86)<\/td>5 (17.86\uff09<\/td>1\uff083.57)<\/td>28 (14.43)<\/td><\/tr>
Total<\/td>62 (31.96)<\/td>103 (53.09)<\/td>26 (13.40\uff09<\/td>3\uff081.55)<\/td>194 (100.00)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

*Other: Cook Islands, Niue are not included in the World Bank Country Income Classification; Venezuela is not yet classified<\/p>\n\n\n\n

The temporal division of immunization schedules based on 2010 (the year PCV13 launched globally) showed that high-income countries had the highest PCV vaccine introduction rate before 2009. Low-income countries had the highest immunization introduction rate after 2010. Around 70% of countries had included PCV vaccine in their national immunization programs after 2010 (Table 2).<\/p>\n\n\n\n

Table<\/strong> <\/strong>2<\/strong> <\/strong>Year of PCV introduction by country income level, <\/strong>n(%)<\/strong><\/p>\n\n\n\n

Incorporation of time classification<\/strong><\/td>World Bank Country Income Classification<\/strong><\/td>Total<\/strong><\/td><\/tr>
 <\/td>High-income countries<\/strong><\/td>Upper middle-income countries<\/strong><\/td>Lower middle-income countries<\/strong><\/td>Low-income countries<\/strong><\/td>Other<\/strong><\/td> <\/td><\/tr>
2000-2009<\/td>34 (77.27%)<\/td>6 (13.64%)<\/td>2 (4.55%)<\/td>1 (2.27%)<\/td>1 (2.27%)*<\/sup><\/strong><\/td>44 (29.93%)<\/td><\/tr>
2010-2020<\/td>17 (16.50%)<\/td>27 (26.21%)<\/td>19 (18.45%)<\/td>40 (38.83%)<\/td>0 (0.00%)<\/td>103 (70.07%)<\/td><\/tr>
*Niue incorporated PCV vaccine into the national immunization programme in 2009<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Immunization schedules varied among countries. Based on a survey in 2018, 118 of WHO’s 140 Member States implemented 3-dose PCV immunization schedule, 21 countries implementing a 4-dose PCV immunization schedule, and 1 country implementing a \u22655-dose PCV immunization schedule. Most countries in the African Zone chose a 3-dose primary immunization with a starting age of 1.5 months, while most countries in the American Region and the European Region chose a 2 primary doses schedule with 1-dose booster, often starting at age of 2 months.2<\/sup><\/p>\n\n\n\n

Content Editor: Menglu Jiang, Ziqi Liu<\/p>\n\n\n\n

Page Editor: Ziqi Liu<\/p>\n\n\n\n

\n\n\n\n

References<\/strong><\/p>\n\n\n\n

    \n
  1. World Health Organization. Introduction of PCV (Pneumococcal conjugate vaccine) [EB\/OL].[2024-07-30]. https:\/\/immunizationdata.who.int\/global\/wiise-detail-page\/introduction-of-pcv-(pneumococcal-conjugate-vaccine)?ISO_3_CODE=&YEAR=<\/li>\n\n\n\n
  2. Wu D, Ning G, Li J, Yin Z, Li Y. Vaccination schedules of PCV and PPV in 140 member states of World Health Organization. Chinese Journal of Public Health,2018,34(11):1476-1479.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    The World Health Organization (WHO) recommends the introduction of pneumococcal vaccines into the immunization schedules of all member states. By the end of 2023, 166 countries had done so, with a global coverage rate of approximately 65% for the final PCV dose. Among countries that have introduced PCV, there are 62 high-income countries (31.96%) and […]<\/p>\n","protected":false},"author":13,"featured_media":0,"parent":12981,"menu_order":6,"template":"","format":"standard","meta":{"articles_list_all":"","type_label":"none_selected"},"evidence-tag-expert":[120],"class_list":["post-15057","evidence-db-expert","type-evidence-db-expert","status-publish","format-standard","hentry","evidence-tag-expert-pcv"],"_links":{"self":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/evidence-db-expert\/15057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/evidence-db-expert"}],"about":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/types\/evidence-db-expert"}],"author":[{"embeddable":true,"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/users\/13"}],"up":[{"embeddable":true,"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/evidence-db-expert\/12981"}],"wp:attachment":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/media?parent=15057"}],"wp:term":[{"taxonomy":"evidence-tag-expert","embeddable":true,"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/evidence-tag-expert?post=15057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}